BioMarin reports record Q2 revenues of $534M; raises FY2022 guidance on Voxzogo growth

BIOMARIN PHARMACEUTICAL INC

2022-Q2 EPS reported $0.79 revenue$1,053,157,000

Total revenues $533.8M (+6% YoY); GAAP net income $27.7M vs $12.9M in Q2 2021.
Voxzogo contributed $34.4M (first full quarter of U.S./EU sales); 446 children treated globally as of June 30.
FY2022 total revenue guidance raised to $2.06-2.16B; Voxzogo net product revenue guidance raised to $130-160M.
Expects EC approval of Roctavian for hemophilia A in Q3; BLA resubmission in U.S. planned for September 2022.
Kuvan revenues declined 27% YoY to $57.6M due to generic competition; total revenues growth excluding Kuvan was 13% YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.